Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This review examines alopecia as a side effect of psychotropic medications, noting that it is typically reversible after stopping the drug, but it reports no new results.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This study expands the Drug Ontology to include therapeutic indications for resistant hypertension, malaria, and opioid abuse research, providing a framework for additional drug use representations beyond their original design.

This chapter reviews pharmacodynamic evaluations in endocrine disorders focusing on oral antidiabetics, insulin analogues, and hormone interactions, but reports no new results.

The document listed various medical job opportunities with competitive benefits and living conditions.

Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.

This study found that prototype right heart circulatory assist devices significantly improved hemodynamics and reduced pulmonary vascular resistances in piglet models of acute hemodynamic shock.

In this study, the combination of metoprolol and spironolactone in patients with coronary heart disease and heart failure significantly improved cardiac function and reduced inflammation and oxidative stress markers compared to spironolactone alone, with better clinical efficacy and fewer adverse effects.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

This review discusses the therapeutic potential of potassium channel openers for various conditions, but notes that their clinical role is not yet fully established.

This study found that minoxidil increased plasma renin activity in patients with hypertension through both an adrenergic mechanism related to heart rate changes and a secondary mechanism unrelated to propranolol.

This case report details a woman with postural orthostatic tachycardia syndrome who experienced notable dermatological symptoms, including evanescent hyperemia, which improved with the use of an oral angiotensin II type 1 receptor antagonist.

This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.

This study found that switching patients with glaucoma or ocular hypertension from benzalkonium chloride-latanoprost to preservative-free latanoprost maintained intraocular pressure control and improved tolerability, potentially enhancing treatment adherence and quality of life.

This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.

Metoprolol and propranolol may cause hair loss.

This article reviews the therapeutic potential of potassium channel openers for various conditions related to metabolic distress but does not report new clinical results; it emphasizes the need for further research.

Minoxidil can cause hair growth as a side effect.

Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

This case report suggests that lisinopril may cause alopecia, which resolved after the patient switched to losartan potassium.

Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.

In isolated rat lymph vessels, this study found that ATP-sensitive potassium channel openers impair lymph contractions and reduce lymph flow, potentially contributing to peripheral edema.